Gleison Tibau Sure That 100% Of Fighters Are Using Illegal Substances

MMA

Brazilian lightweight Gleison Tibau is going to be seeing his two year USADA issued suspension come to an end in just a little over a week.

The Brazilian was suspended fighter had a substance known as erythropoietin in his system and that caused him to fail two separate USADA issued drug tests.

UFC Fighters Told They'll Be Using Old-Style Gloves At UFC 309 In Madison Square Garden

Despite being caught with the illegal substance, the fighter is fairly certain that just about every fighter have used the same stuff.

"It’s a substance that no UFC athlete will point a finger at me and say anything because everyone else used it,” Tibau told MMA Fighting. “I’m 100 percent sure everyone else used it. I was the first fighter to get caught with this new USADA rule. I was misinformed that this substance wasn’t allowed with USADA. I needed it because my tests showed I had low red blood cells, so I needed that to get better."

When Tibau does return to action, it is going to be his first fight since a bout against Abel Trujillo at UFC Fight Night 77 in November of 2015.

Tibau is now sitting back and waiting to get himself back into action, which would end the worst two years of his life.

"After two long years, I’m just waiting for my next fight,” Tibau said. “The UFC guaranteed me I’ll fight in December, so I’m just waiting. It was the worst two years of my life. Imagine yourself going to the gym every day knowing that you can’t fight for two years. I didn’t sleep well several times. Money became a problem. Fighters only make money when they are competing, but bills won’t stop coming. Months and months without fights, that disturbed me. That really disturbed me. I thought about doing something else, following a different path. A lot of things crossed my mind.”

If Tibau does return in December like he claimed, then he could be competing at UFC 218, UFC 219, UFC On Fox 26 or UFC Fight Night Fresno.

Get exclusive pro wrestling content on Fightful Select, our premium news service! Click here to learn more.